TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $170,915 | -37.5% | 19,118 | +7.4% | 0.00% | -50.0% |
| Q2 2023 | $273,362 | -23.1% | 17,797 | +12.6% | 0.00% | -33.3% |
| Q1 2023 | $355,454 | +10.2% | 15,805 | +3.0% | 0.00% | 0.0% |
| Q4 2022 | $322,600 | -10.6% | 15,340 | +4.6% | 0.00% | -25.0% |
| Q3 2022 | $361,000 | +2.3% | 14,671 | +0.8% | 0.00% | +33.3% |
| Q2 2022 | $353,000 | -8.1% | 14,561 | -2.2% | 0.00% | 0.0% |
| Q1 2022 | $384,000 | -16.0% | 14,895 | +1.3% | 0.00% | 0.0% |
| Q4 2021 | $457,000 | +27.3% | 14,708 | -0.8% | 0.00% | 0.0% |
| Q3 2021 | $359,000 | +74.3% | 14,821 | +5.2% | 0.00% | +50.0% |
| Q2 2021 | $206,000 | -45.4% | 14,092 | -6.6% | 0.00% | -33.3% |
| Q1 2021 | $377,000 | +10.2% | 15,091 | +20.3% | 0.00% | 0.0% |
| Q4 2020 | $342,000 | – | 12,548 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |